Wall Street Zen Upgrades Bluejay Diagnostics (NASDAQ:BJDX) to Sell

Bluejay Diagnostics (NASDAQ:BJDX) was upgraded by investment analysts at Wall Street Zen to a “sell” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

Bluejay Diagnostics Price Performance

NASDAQ BJDX opened at $1.45 on Friday. The stock’s 50-day simple moving average is $2.64 and its two-hundred day simple moving average is $2.44. Bluejay Diagnostics has a twelve month low of $1.03 and a twelve month high of $16.68. The company has a market capitalization of $1.49 million, a price-to-earnings ratio of -0.12 and a beta of 0.88.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.95) earnings per share (EPS) for the quarter.

Insider Activity at Bluejay Diagnostics

In other Bluejay Diagnostics news, major shareholder Financial Lp Hrt bought 64,047 shares of Bluejay Diagnostics stock in a transaction that occurred on Thursday, July 9th. The shares were bought at an average price of $1.51 per share, with a total value of $96,710.97. Following the acquisition, the insider owned 126,993 shares in the company, valued at approximately $191,759.43. This trade represents a 101.75% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 6.10% of the company’s stock.

Institutional Trading of Bluejay Diagnostics

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new position in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics at the end of the most recent quarter. Institutional investors own 18.47% of the company’s stock.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.